Companies › Shanghai Huaota Biopharmaceutical
5 active drug programs in 7 registered trials: 5 Phase 1, 1 Phase 3, 1 Phase 2; Other, Oncology, Immunology, Respiratory; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HB0025 Injection | – | Phase 3 | First-line pMMR Endometrial Cancer | Apr 2029 |
| HB0034 anti-IL-36R monoclonal antibody | IL36R | Phase 2 | Generalized Pustular Psoriasis (GPP); Healthy | – |
| HB0056 Bispecific antibody targeting TSLP and IL-11 | TSLP, IL11 | Phase 1 | Healthy; Asthma | Aug 2027 |
| HB0036 Anti-PD-L1 and anti-TIGIT bifunctional molecule | CD274, TIGIT | Phase 1 | Advanced Solid Tumor | – |
| HB0043 | – | Phase 1 | Hidradenitis Suppurativa | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06231381 | HB0034 | Phase 2 | Generalized Pustular Psoriasis (GPP) | Immunology | Feb 2025 |
| NCT06612970 | HB0056 | Phase 1 | Healthy | Other | Jun 2025 |
| NCT05417321 | HB0036 | Phase 1 | Advanced Solid Tumor | Oncology | Aug 2025 |
| NCT06716151 | HB0034 | Phase 1 | Healthy | Other | Nov 2025 |
| NCT06895499 | HB0043 | Phase 1 | Hidradenitis Suppurativa | Immunology | Jan 2026 |
| NCT07899996 | HB0056 | Phase 1 | Asthma | Respiratory | Aug 2027 |
| NCT07902999 | HB0025 Injection | Phase 3 | First-line pMMR Endometrial Cancer | Oncology | Apr 2029 |
Beijing Tide Pharmaceutical HC Biopharma Chengdu Zenitar Biomedical Technology Haihe Biopharma Yuhan
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.